Our research group evaluated the complexes for the treatment of MPS I mice (mucopolysaccharidosis type I) in order to correct the defect in the gene of the alpha-L-iduronidase enzyme (IDUA, EC 3.2.1.76), responsible for the catabolism of the glycosaminoglycans (GAGs) dermatan and heparan sulfate [7]. The gene discussed is IDUA; the disease is Scheie syndrome.